JANX vs. BMY
JANX (Janux Therapeutics, Inc.) and BMY (Bristol-Myers Squibb Company) are both stocks. Both are in the Healthcare sector — JANX in Biotechnology, BMY in Drug Manufacturers - General. Over the past 5 years, JANX returned -9.52%/yr vs 1.42%/yr for BMY. At a 0.18 correlation, their price movements are largely independent.
Performance
JANX vs. BMY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, JANX achieves a 16.96% return, which is significantly higher than BMY's 13.73% return.
JANX
- 1D
- -1.59%
- 1M
- 19.03%
- 6M
- 15.04%
- YTD
- 16.96%
- 1Y
- -35.83%
- 3Y*
- 9.01%
- 5Y*
- -9.52%
- 10Y*
- —
BMY
- 1D
- 3.06%
- 1M
- 5.04%
- 6M
- 8.71%
- YTD
- 13.73%
- 1Y
- 32.71%
- 3Y*
- 3.33%
- 5Y*
- 1.42%
- 10Y*
- 1.05%
JANX vs. BMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
JANX Janux Therapeutics, Inc. | 16.96% | -74.22% | 398.97% | -18.53% | -33.25% | -41.97% |
BMY Bristol-Myers Squibb Company | 13.73% | 0.11% | 15.81% | -26.14% | 18.98% | -6.04% |
Correlation
The correlation between JANX and BMY is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.27 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.24 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.19 |
Correlation (All Time) Calculated using the full available price history since Jun 11, 2021 | 0.18 |
Fundamentals
JANX:
$984.29M
BMY:
$121.18B
JANX:
-$1.84
BMY:
$3.56
JANX:
46.46
BMY:
2.50
JANX:
1.07
BMY:
6.04
JANX:
$21.61M
BMY:
$48.48B
JANX:
$8.44M
BMY:
$33.33B
JANX:
-$134.03M
BMY:
$13.34B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
JANX vs. BMY — Risk / Return Rank
JANX
BMY
JANX vs. BMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Janux Therapeutics, Inc. (JANX) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| JANX | BMY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.67 | ||
| Sortino ratioReturn per unit of downside risk | -2.01 | ||
| Omega ratioGain probability vs. loss probability | 0.97 | 1.22 | -0.24 |
| Calmar ratioReturn relative to maximum drawdown | -0.55 | 2.62 | -3.18 |
| Martin ratioReturn relative to average drawdown | -0.78 | 5.74 | -6.52 |
Loading charts...
Drawdowns
JANX vs. BMY - Drawdown Comparison
The maximum JANX drawdown since its inception was -83.14%, which is greater than BMY's maximum drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for JANX and BMY.
Loading charts...
Drawdown Indicators
| JANX | BMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.14% | -72.03% | -11.11% |
Max Drawdown (1Y)Largest decline over 1 year | -64.94% | -12.53% | -52.41% |
Max Drawdown (3Y)Largest decline over 3 years | -81.78% | -36.02% | -45.76% |
Max Drawdown (5Y)Largest decline over 5 years | -83.14% | -47.67% | -35.47% |
Max Drawdown (10Y)Largest decline over 10 years | — | -47.67% | — |
Current DrawdownCurrent decline from peak | -75.85% | -13.64% | -62.21% |
Average DrawdownAverage peak-to-trough decline | -53.01% | -22.37% | -30.64% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 46.22% | 5.71% | +40.51% |
Volatility
JANX vs. BMY - Volatility Comparison
Janux Therapeutics, Inc. (JANX) has a higher volatility of 11.90% compared to Bristol-Myers Squibb Company (BMY) at 9.18%. This indicates that JANX's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| JANX | BMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.90% | 9.18% | +2.72% |
Volatility (6M)Calculated over the trailing 6-month period | 30.76% | 18.90% | +11.86% |
Volatility (1Y)Calculated over the trailing 1-year period | 74.44% | 27.70% | +46.74% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 130.69% | 24.33% | +106.36% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 130.62% | 25.40% | +105.22% |
Dividends
JANX vs. BMY - Dividend Comparison
JANX has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.23%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 4.23% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
JANX Janux Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
JANX vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Janux Therapeutics, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
JANX and BMY have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
JANX has higher volatility (11.90%) compared to BMY (9.18%). In terms of maximum drawdown, JANX dropped -83.14% vs BMY's -72.03%.
BMY currently has the higher Sharpe Ratio (1.19 vs -0.48), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for JANX and BMY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer